Roche's Tamiflu ineffective against primary flu strain for this season; GSK's Relenza set to take over
Swiss drug major Roche's gold-standard flu medicine Tamiflu (oseltamivir) is ineffective against the main type of influenza set to affect the USA this season, says Centers for Disease Control and Prevention (CDC).
From October 1 to December 13, 2008, the CDC tested 50 H1N1 influenza A strains, eight H3N2, and 20 influenza B viruses from 15 US states for resistance to two groups of antiviral drugs: neuraminidase inhibitors, such as Tamiflu, and adamantanes. The H1N1 strain was found to be resistant to the Roche drug in 49, or 98%, of the samples tested.
CDC says still too early to predict which strain will be prevalent
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze